Investigational drug · Phase 2
Balstilimab
Also called: AGEN2034
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
56
Any phase or sponsor naming "Balstilimab"
First trial start
2021
Nov 23, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Balstilimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metastatic Prostate Cancer
- Metastatic Head and Neck Squamous Cell Carcinoma
- Metastatic Pancreatic Cancer
- Metastatic Colorectal Cancer
- Refractory Metastatic Colorectal Cancer
- Solid Tumor
- Metastatic Microsatellite-stable Colorectal Cancer
- Mismatch Repair Protein Proficient
- Metastatic GI Cancers
- Gastric Cancer
Approved drugs for the same conditions: Prostate cancer · Colorectal cancer · Pancreatic cancer · Stomach and esophageal cancer · Head and neck cancer · Oncology · Kidney and urology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Balstilimab" as an intervention, largest first.
- Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced CancerActive, not recruiting
Agenus Inc.Industry
NCT03860272 · 499 participants · Start Mar 20, 2019 · Primary completion Jan 13, 2025
Drug: Botensilimab; Balstilimab · For: Advanced Cancer; Angiosarcoma; Colorectal Cancer Without Liver Metastases and 5 more
Sites: Scottsdale, Arizona; Duarte, California; Los Angeles, California · 18 sites in all
- A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and ChemotherapyPivotal-lookingRecruiting
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
NCT07227636 · 284 participants (planned) · Start Nov 7, 2025 · Primary completion Nov 2030
Drug: Botensilimab; Balstilimab · For: Colorectal Cancer; Rectal Cancer
Sites: Basking Ridge, New Jersey; Middletown, New Jersey; Montvale, New Jersey · 7 sites in all
- A Study of Botensilimab and Balstilimab for the Treatment of Colorectal CancerPivotal-lookingActive, not recruiting
Agenus Inc.Industry
NCT05608044 · 234 participants · Start Nov 30, 2022 · Primary completion Sep 2027
Drug: Botensilimab; Balstilimab and 1 more · For: Metastatic Colorectal Cancer
Sites: Scottsdale, Arizona; Duarte, California; Los Angeles, California · 65 sites in all
- RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical CancerPivotal-lookingTerminated
Agenus Inc.Industry
NCT03894215 · 211 participants · Start Jun 1, 2019 · Primary completion Mar 26, 2025
Drug: AGEN2034; AGEN1884 · For: Cervical Cancer
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 68 sites in all
Agenus Inc.Industry
NCT03104699 · 211 participants · Start Apr 11, 2017 · Primary completion Jun 15, 2022
Drug: AGEN2034 · For: Advanced Cancer; Cervical Cancer
Sites: Scottsdale, Arizona; Duarte, California; Los Angeles, California · 44 sites in all
- Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid TumorsActive, not recruiting
Oxford BioTherapeutics LtdIndustry
NCT04064359 · 200 participants (planned) · Start Jul 25, 2019 · Primary completion Dec 31, 2027
Drug: OBT076, a CD205-directed antibody-drug conjugate · For: Solid Tumor
Sites: Phoenix, Arizona; Los Angeles, California; Santa Monica, California · 27 sites in all
- Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)Recruiting
Gruppo Oncologico del Nord-OvestAcademic, hospital or other
NCT05845450 · 197 participants (planned) · Start May 11, 2023 · Primary completion May 2027
Drug: Trastuzumab deruxtecan; Durvalumab and 9 more · For: Colorectal Cancer; Resectable Colorectal Carcinoma
Sites: Milan, Italy
Agenus Inc.Industry
NCT03495882 · 175 participants · Start Dec 18, 2017 · Primary completion Jul 15, 2022
Drug: Zalifrelimab; Balstilimab · For: Cervical Cancer
Sites: Goodyear, Arizona; Duarte, California; Miami, Florida · 47 sites in all
- A Study of Botensilimab (AGEN1181) for the Treatment of Advanced MelanomaPivotal-lookingTerminated
Agenus Inc.Industry
NCT05529316 · 150 participants · Start Dec 12, 2022 · Primary completion Apr 27, 2026
Drug: Botensilimab; Balstilimab · For: Advanced Melanoma
Sites: Scottsdale, Arizona; Fullerton, California; Santa Monica, California · 51 sites in all
- Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology CombinationsPivotal-lookingRecruiting
The Netherlands Cancer InstituteAcademic, hospital or other
NCT06279130 · 133 participants (planned) · Start Jan 29, 2024 · Primary completion Jan 29, 2029
Drug: botensilimab; balstilimab and 1 more · For: Resectable MMR-deficient Solid Tumors; Resectable MMR-proficient Solid Tumors
Sites: Amsterdam, Netherlands
Newest research
PubMed records naming it or its code names, newest first.
- Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair-Proficient and -Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial.
Shah MA, Hissong E, Jafari MD, et al. · Clin Cancer Res 2026
- Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases.
Schlechter BL, Fakih MG, Tsimberidou AM, et al. · Clin Cancer Res 2026
- Neoadjuvant botensilimab with or without balstilimab in pMMR and dMMR colon cancer: the phase 2 UNICORN trial.
Ghelardi F, Ambrosini M, Raimondi A, et al. · Nat Med 2026
- Immunotherapy in Colorectal Cancer: Novel Perspectives and Next Steps.
de Almeida TSC, Braghiroli MIMF, Sabbaga J, et al. · Am J Clin Oncol 2026
- Transcriptomic profiling identifies immunotherapy-responsive phenotypes in microsatellite-stable metastatic colorectal cancer.
Konecny T, Zadirako N, Grigoryan A, et al. · Oncogene 2026
- WIN-MTB-2024017 - WIN International Molecular Tumor Board: A 48-year-old female with multiple primary cancers.
El-Deiry WS, Hernando-Calvo A, Dizon D, et al. · Oncotarget 2026
Also in development for Metastatic Prostate Cancer
- PalacaparibAZD9574Phase 25 trials
AstraZeneca · Metastatic Prostate Cancer, Ovarian Cancer, Endometrial Cancer
- FPI-2265AZD2265, 225Ac-PSMA-I&TPhase 24 trials
Fusion Pharmaceuticals Inc. · Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer, Metastatic Castration Resistant Prostate Cancer
- AZD2287Imaging agentPhase 22 trials
AstraZeneca · Metastatic Prostate Cancer
- ZalifrelimabPhase 22 trials
ImmunoGenesis · Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Cancer
- AZD0516Phase 21 trial
AstraZeneca · Metastatic Prostate Cancer
- AZD0754Phase 21 trial
AstraZeneca · Metastatic Prostate Cancer
- AZD8359Phase 21 trial
AstraZeneca · Metastatic Prostate Cancer
- GDC-1261Phase 21 trial
Roche (Genentech) · Advanced Prostate Cancer, Metastatic Prostate Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.